TP53 and myelodysplastic syndrome: In a prospective clinical trial of decitabine (10-day courses) to treat AML or transfusion-dependent MDS, patients with TP53 mutations achieved a significantly higher clinical response rate (100%, 21/21) than patients with wildtype TP53 (41%, 32/78).